COST
38
-3
K
44
-3
GRMN
28
-5
BRK.B
33
-3
BAC
35
-6
AA
19
-2
CRM
25
-9
ILMN
17
-5
KLAC
52
-7
IFF
29
-4
ADI
40
-9
CMG
44
-4
CAT
29
-6
ES
7
-5
CF
27
-3
EMR
33
-7
APA
19
-5
AN
38
-8
ALLE
41
-3
KIM
56
-2
COST
38
-3
K
44
-3
GRMN
28
-5
BRK.B
33
-3
BAC
35
-6
AA
19
-2
CRM
25
-9
ILMN
17
-5
KLAC
52
-7
IFF
29
-4
ADI
40
-9
CMG
44
-4
CAT
29
-6
ES
7
-5
CF
27
-3
EMR
33
-7
APA
19
-5
AN
38
-8
ALLE
41
-3
KIM
56
-2
Financhill
Back

Akebia Therapeutics 10K Form

Sell
29

AKBA
Akebia Therapeutics

Last Price:
$1.55
Seasonality Move:
9.5%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AKBA News And Ratings

See the #1 stock for the next 7 days that we like better than AKBA

AKBA Financial Statistics

Sales & Book Value

Annual Sales: $160.2M
Cash Flow: $-4.5M
Price / Cash Flow: 0
Annual Sales: $-0.22
Price / Book: 0

Profitability

EPS (TTM): -0.33000
Net Income (TTM): $-69.4M
Gross Margin: $97M
Return on Equity: 0%
Return on Assets: -31.12%

Akebia Therapeutics Earnings Forecast

Key Akebia Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 12 years for AKBA is 60.56%.
  • The Selling, General & Administrative Expenses for AKBA have been equal to 66.52% of Gross Profit Margin.
  • The Research & Development expenses have been 23.51% of Revenue.
  • The Net Earning history of AKBA is -43.33% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 6 years.

Akebia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AKBA
CUSIP: 00972D
Website: akebia.com

Debt

Debt-to-Equity Ratio: -0.79
Current Ratio: 1.41
Quick Ratio: 1.07

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 20.67

AKBA Technical Analysis vs Fundamental Analysis

Sell
29
Akebia Therapeutics (AKBA) is a Sell

Is Akebia Therapeutics a Buy or a Sell?